Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia
Conditions
Keywords
CML, ALL, PH, ponatinib, Ph+ALL, T315I mutation, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Brief summary
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation.
Detailed description
The preliminary analysis of the phase 1 clinical trial revealed evidence of clinical antitumor activity in patients with resistance to approved second-generation tyrosine kinase inhibitors (TKI), dasatinib and nilotinib, including patients with the T315I mutation of the BCR-ABL gene (BCR-ABL). This Phase 1 study, taken together with the strong preclinical data that characterize ponatinib, provides the rationale for moving to a pivotal phase 2 trial of this agent in a population of patients with chronic myeloid leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) who are resistant or intolerant to prior TKI therapy and in those patients with the T315I mutation. PACE is a multi-center, international, phase 2, uncontrolled, open-label trial of oral ponatinib in patients with Philadelphia chromosome-positive (Ph+) disease. The study enrolled 449 patients. Participants assigned to 1 of 6 cohorts in accordance with disease group and received: * Ponatinib 45 mg This multi-center trial is conducted worldwide. The overall time to participate in this study is 96 months after last dose of study drug treatment.
Interventions
DRUGPonatinib
Ponatinib tablets.
Sponsors
Ariad Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL * Previously treated with and developed resistance or intolerance to dasatinib or nilotinib OR developed the T3151 mutation after any tyrosine kinase inhibitor (TKI) therapy * ≥18 years old * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Minimum life expectancy of ≥3 months * Adequate kidney function * Adequate liver function * Normal pancreatic function * Normal QT Fridericia-corrected interval (QTcF) ≤450 ms for males and ≤470 ms for females * Negative pregnancy test (if woman of childbearing potential) * Agree to use effective form of contraception (as applicable) * Ability to comply with study procedures, in the Investigator's opinion
Exclusion criteria
* Received prior TKI treatment within 7 days prior to receiving the first dose of ponatinib, or have not recovered from adverse events (except alopecia) due to agents previously administered. * Received other therapies as follows: 1. For CML chronic phase (CP) and accelerated phase (AP) participants, received hydroxyurea or anagrelide within 24 hours prior to receiving the first dose of ponatinib; interferon, cytarabine, or immunotherapy within 14 days prior to first dose of ponatinib; or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of ponatinib. 2. For CML blast phase (BP) participants, received chemotherapy within 14 days prior to the first dose of ponatinib. 3. For Ph+ ALL participants, received corticosteroids within 24 hours before the first dose of ponatinib; or vincristine within 7 days prior to the first dose of ponatinib; or received other chemotherapy within 14 days prior to the first dose of ponatinib. * Underwent stem cell transplant \<60 days prior to receiving first dose of ponatinib * Evidence of on-going graft versus-host disease (GVHD), or GVHD requiring immunosuppressive therapy * Taking medications that are known to be associated with Torsades de Pointes * Require concurrent treatment with immunosuppressive agents (other than corticosteroids prescribed for a short course of therapy) * Previously treated with ponatinib * CML CP participants are excluded if they are in Complete cytogenetic response (CCyR) * Participants with CML AP, CML BP, or Ph+ ALL are excluded if they are in Major Hematologic Response (MaHR). * Have active Central Nervous System (CNS) disease * Have significant or active cardiovascular disease * Have a significant bleeding disorder unrelated to CML or Ph+ALL * Have a history of pancreatitis or alcohol abuse * Have uncontrolled hypertriglyceridemia (triglycerides \>450 mg/dL) * Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of ponatinib * Diagnosed with another primary malignancy in the past 3 years * Pregnant or lactating * Underwent major surgery within 14 days prior to first dose of ponatinib * Have ongoing or active infection * Suffer from any other condition or illness that would compromise safety or interfere with evaluation of the drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) | Up to 12 months after initiation of study treatment | MCyR is defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: no Ph+ cells; PCyR: 1 to 35% Ph+ cells. |
| Percentage of AP-CML Participants With Major Hematologic Response (MaHR) | Up to 6 months after initiation of study treatment | MaHR is defined as percentage of participants with complete hematologic response (CHR) or no evidence of leukemia (NEL). Response criteria for CHR is reported as white blood cells (WBC)≤institutional upper limit of normal, absolute neutrophil count (ANC)≥1000/mm\^3, platelets≥100,000/mm\^3, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement; Response criteria for NEL is reported as WBC≤institutional upper limit of normal, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement, at least 1 of the following: (i) 20,000/mm\^3≤platelets\<100,000/mm\^3; (ii) 500/mm\^3≤ANC\<1000/mm\^3. |
| Percentage of BP-CML/Ph+ ALL Participants With MaHR | Up to 6 months after initiation of study treatment | MaHR is defined as percentage of participants with CHR or NEL. Response criteria for CHR is reported as WBC≤institutional upper limit of normal, ANC≥1000/mm\^3, platelets ≥100,000/mm\^3, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement; Response criteria for NEL is reported as WBC≤ institutional upper limit of normal, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement, at least 1 of the following: (i) 20,000/mm\^3 ≤platelets\<100,000/mm\^3; (ii) 500/mm\^3≤ANC\<1000/mm\^3. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MCyR | Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose) | MCyR is defined as percentage of participants with CCyR or PCyR. Cytogenetic response is the percentage of Ph+ metaphases in BM. Response is further defined as MCyR: CCyR or PCyR, where CCyR: no Ph+ cells; PCyR: 1 to 35% Ph+ cells. |
| Percentage of AP-CML or BP-CML/Ph+ ALL Participants With Confirmed MCyR | Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose) | Confirmed MCyR is defined as 2 assessments of CCyR or PCyR at least 28 days apart. |
| Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MMR | Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose) | MMR is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript). |
| Time to Response | Up to approximately 48 months after first dose | Time to response is defined as the interval from the first dose of study treatment until the criteria for response are first met, censored at the last assessment of response. Median time to response was estimated using the Kaplan-Meier method. |
| Percentage of CP-CML Participants With CHR | Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose) | Response criteria for CHR is reported as WBC≤institutional upper limit of normal, platelets\<450,000/mm\^3, no blasts or promyelocytes in peripheral blood, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement (including no hepatomegaly or splenomegaly). |
| Progression-free Survival (PFS) | Every 12 weeks ± 2 weeks from last dose of study drug or the investigator/participant decision to discontinue treatment, whichever occurred later (Up to approximately 96 months after last dose) | PFS is defined as the interval from the first dose of study treatment until the criteria for progression or death are met, censored at the last response assessment. Progression from CP is reported as death, development of AP or BP, loss of CHR (in the absence of cytogenetic response), confirmed by development in complete blood counts (CBCs) at least 4 weeks apart, loss of MCyR, increasing WBC in participant without CHR defined by doubling of WBC to \>20K on 2 occasions at least 4 weeks apart; Progression from AP is reported as death, development of confirmed BP, loss of previous major or minor hematologic response over a 2-week period, no decrease from baseline levels in percentage blasts in peripheral blood or BM on all assessments over a 4-week period; Progression from BP or Ph+ ALL is reported as death, increasing blasts in peripheral blood or BM over a 4 week period. |
| Overall Survival (OS) | From the first dose of study treatment until death (Up to 96 months post last dose) | OS is defined as the interval from the first dose of study treatment until death, censored at the last date at which participant was known to be alive. |
| Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | From first dose up to 30 days after last dose of the study drug (Up to approximately 49 months) | An AE is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy. |
| Duration of Response | Up to approximately 48 months after first dose | Duration of Response is defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met, censored at the last date at which the criteria for response are met. Duration of response was estimated by the Kaplan-Meier method as the probability of remaining in response. |
| Percentage of CP-CML Participants With Confirmed MCyR | Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose) | Confirmed MCyR is defined as 2 assessments of CCyR or PCyR at least 28 days apart. For CP participants entering the trial in PCyR, confirmed MCyR is defined as 2 assessments of CCyR at least 28 days apart. |
| Percentage of CP-CML Participants With Major Molecular Response (MMR) | Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose) | MMR is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript). |
Countries
Australia, Belgium, France, Germany, Italy, Netherlands, Singapore, South Korea, Spain, Sweden, United Kingdom
Participant flow
Recruitment details
Participants took part in the study at 66 investigative sites in the Australia, Belgium, Canada, France, Germany, Italy, the Netherlands, Republic of Korea, Singapore, Spain, Sweden, the United Kingdom and the United States from 30 September 2010 to 17 January 2019.
Pre-assignment details
Participants were assigned to 1 of 6 cohorts: chronic myeloid leukemia (CML) in chronic (CP), accelerated (AP), or blast phase (BP), or with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who were resistant or intolerant (R-I) to either dasatinib or nilotinib or had (T)hreonine-315-(I)soleucine (T315I) mutation.
Participants by arm
| Arm | Count |
|---|---|
| Cohort A: CP-CML R-I CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months). | 203 |
| Cohort B: CP-CML With T315I Mutation CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months). | 64 |
| Cohort C: AP-CML R-I AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months). | 65 |
| Cohort D: AP-CML With T315I Mutation AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months). | 18 |
| Cohort E: BP-CML/Ph+ ALL R-I BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months). | 48 |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months). | 46 |
| Unassigned to Cohorts A-F Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not resistant or intolerant to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months). | 5 |
| Total | 449 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 46 | 11 | 7 | 2 | 6 | 6 | 2 |
| Overall Study | Death | 6 | 3 | 2 | 2 | 7 | 5 | 1 |
| Overall Study | Lack of Efficacy | 13 | 2 | 5 | 1 | 2 | 3 | 0 |
| Overall Study | Lost to Follow-up | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Overall Study | Non-compliance with Study Drug | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Physician Decision | 6 | 5 | 5 | 0 | 1 | 0 | 0 |
| Overall Study | Progressive Disease | 19 | 10 | 19 | 7 | 23 | 27 | 0 |
| Overall Study | Protocol Violation | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Reason Not Specified | 10 | 10 | 7 | 0 | 4 | 3 | 0 |
| Overall Study | Site Terminated by Sponsor | 69 | 19 | 12 | 2 | 3 | 0 | 2 |
| Overall Study | Withdrawal by Subject | 29 | 4 | 5 | 3 | 2 | 2 | 0 |
Baseline characteristics
| Characteristic | Total | Unassigned to Cohorts A-F | Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Cohort E: BP-CML/Ph+ ALL R-I | Cohort D: AP-CML With T315I Mutation | Cohort C: AP-CML R-I | Cohort B: CP-CML With T315I Mutation | Cohort A: CP-CML R-I |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 59.0 years | 63.0 years | 56.0 years | 54.0 years | 54.0 years | 60.0 years | 52.0 years | 61.0 years |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ECOG=0 | 267 Participants | 5 Participants | 16 Participants | 15 Participants | 12 Participants | 33 Participants | 47 Participants | 139 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ECOG=1 | 147 Participants | 0 Participants | 19 Participants | 20 Participants | 6 Participants | 25 Participants | 17 Participants | 60 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ECOG=2 | 34 Participants | 0 Participants | 11 Participants | 12 Participants | 0 Participants | 7 Participants | 0 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 42 Participants | 0 Participants | 12 Participants | 2 Participants | 1 Participants | 6 Participants | 8 Participants | 13 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 407 Participants | 5 Participants | 34 Participants | 46 Participants | 17 Participants | 59 Participants | 56 Participants | 190 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized American Indian/Alaska native | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian | 59 Participants | 2 Participants | 7 Participants | 8 Participants | 3 Participants | 8 Participants | 14 Participants | 17 Participants |
| Race/Ethnicity, Customized Black/African American | 25 Participants | 0 Participants | 1 Participants | 1 Participants | 5 Participants | 7 Participants | 4 Participants | 7 Participants |
| Race/Ethnicity, Customized Other | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown | 8 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 3 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 352 Participants | 3 Participants | 38 Participants | 39 Participants | 9 Participants | 47 Participants | 42 Participants | 174 Participants |
| Sex: Female, Male Female | 211 Participants | 3 Participants | 20 Participants | 17 Participants | 7 Participants | 40 Participants | 16 Participants | 108 Participants |
| Sex: Female, Male Male | 238 Participants | 2 Participants | 26 Participants | 31 Participants | 11 Participants | 25 Participants | 48 Participants | 95 Participants |
| Time From Diagnosis to First Dose | 6.09 years | 4.80 years | 1.63 years | 3.96 years | 6.61 years | 7.13 years | 4.78 years | 7.85 years |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 41 / 203 | 18 / 64 | 30 / 65 | 9 / 18 | 40 / 48 | 39 / 46 | 2 / 5 |
| other Total, other adverse events | 203 / 203 | 64 / 64 | 65 / 65 | 18 / 18 | 48 / 48 | 46 / 46 | 5 / 5 |
| serious Total, serious adverse events | 132 / 203 | 39 / 64 | 44 / 65 | 13 / 18 | 41 / 48 | 37 / 46 | 3 / 5 |
Outcome results
Primary
Percentage of AP-CML Participants With Major Hematologic Response (MaHR)
MaHR is defined as percentage of participants with complete hematologic response (CHR) or no evidence of leukemia (NEL). Response criteria for CHR is reported as white blood cells (WBC)≤institutional upper limit of normal, absolute neutrophil count (ANC)≥1000/mm\^3, platelets≥100,000/mm\^3, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement; Response criteria for NEL is reported as WBC≤institutional upper limit of normal, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement, at least 1 of the following: (i) 20,000/mm\^3≤platelets\<100,000/mm\^3; (ii) 500/mm\^3≤ANC\<1000/mm\^3.
Time frame: Up to 6 months after initiation of study treatment
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts C and D only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of AP-CML Participants With Major Hematologic Response (MaHR) | 56.9 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of AP-CML Participants With Major Hematologic Response (MaHR) | 55.6 percentage of participants |
Primary
Percentage of BP-CML/Ph+ ALL Participants With MaHR
MaHR is defined as percentage of participants with CHR or NEL. Response criteria for CHR is reported as WBC≤institutional upper limit of normal, ANC≥1000/mm\^3, platelets ≥100,000/mm\^3, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement; Response criteria for NEL is reported as WBC≤ institutional upper limit of normal, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement, at least 1 of the following: (i) 20,000/mm\^3 ≤platelets\<100,000/mm\^3; (ii) 500/mm\^3≤ANC\<1000/mm\^3.
Time frame: Up to 6 months after initiation of study treatment
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts E and F only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of BP-CML/Ph+ ALL Participants With MaHR | 35.4 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of BP-CML/Ph+ ALL Participants With MaHR | 32.6 percentage of participants |
Primary
Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR)
MCyR is defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: no Ph+ cells; PCyR: 1 to 35% Ph+ cells.
Time frame: Up to 12 months after initiation of study treatment
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts A and B only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) | 50.7 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) | 70.3 percentage of participants |
Secondary
Duration of Response
Duration of Response is defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met, censored at the last date at which the criteria for response are met. Duration of response was estimated by the Kaplan-Meier method as the probability of remaining in response.
Time frame: Up to approximately 48 months after first dose
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. Number analyzed is number of participants with data available for analysis at given time-point
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Cohort A: CP-CML R-I | Duration of Response | Hematologic Response | NA days |
| Cohort A: CP-CML R-I | Duration of Response | Cytogenetic Response | NA days |
| Cohort A: CP-CML R-I | Duration of Response | Molecular Response | NA days |
| Cohort B: CP-CML With T315I Mutation | Duration of Response | Hematologic Response | NA days |
| Cohort B: CP-CML With T315I Mutation | Duration of Response | Cytogenetic Response | NA days |
| Cohort B: CP-CML With T315I Mutation | Duration of Response | Molecular Response | NA days |
| Cohort E: BP-CML/Ph+ ALL R-I | Duration of Response | Molecular Response | 560.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Duration of Response | Hematologic Response | 360.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Duration of Response | Cytogenetic Response | NA days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Duration of Response | Cytogenetic Response | 728.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Duration of Response | Hematologic Response | 732.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Duration of Response | Molecular Response | 222.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Duration of Response | Hematologic Response | 196.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Duration of Response | Cytogenetic Response | NA days |
| Cohort E: BP-CML/Ph+ ALL R-I | Duration of Response | Molecular Response | NA days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Duration of Response | Cytogenetic Response | 63.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Duration of Response | Molecular Response | 98.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Duration of Response | Hematologic Response | 108.0 days |
Secondary
Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE)
An AE is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy.
Time frame: From first dose up to 30 days after last dose of the study drug (Up to approximately 49 months)
Population: The safety population included all participants who received at least 1 dose of ponatinib.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort A: CP-CML R-I | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | TEAE | 203 Participants |
| Cohort A: CP-CML R-I | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | SAE | 132 Participants |
| Cohort B: CP-CML With T315I Mutation | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | TEAE | 64 Participants |
| Cohort B: CP-CML With T315I Mutation | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | SAE | 39 Participants |
| Cohort E: BP-CML/Ph+ ALL R-I | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | TEAE | 65 Participants |
| Cohort E: BP-CML/Ph+ ALL R-I | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | SAE | 44 Participants |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | TEAE | 18 Participants |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | SAE | 13 Participants |
| Cohort E: BP-CML/Ph+ ALL R-I | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | TEAE | 48 Participants |
| Cohort E: BP-CML/Ph+ ALL R-I | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | SAE | 41 Participants |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | TEAE | 46 Participants |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | SAE | 37 Participants |
| Unassigned to Cohorts A-F | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | TEAE | 5 Participants |
| Unassigned to Cohorts A-F | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | SAE | 3 Participants |
Secondary
Overall Survival (OS)
OS is defined as the interval from the first dose of study treatment until death, censored at the last date at which participant was known to be alive.
Time frame: From the first dose of study treatment until death (Up to 96 months post last dose)
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: CP-CML R-I | Overall Survival (OS) | NA days |
| Cohort B: CP-CML With T315I Mutation | Overall Survival (OS) | NA days |
| Cohort E: BP-CML/Ph+ ALL R-I | Overall Survival (OS) | 1689.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Overall Survival (OS) | 1847.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Overall Survival (OS) | 209.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Overall Survival (OS) | 200.0 days |
Secondary
Percentage of AP-CML or BP-CML/Ph+ ALL Participants With Confirmed MCyR
Confirmed MCyR is defined as 2 assessments of CCyR or PCyR at least 28 days apart.
Time frame: Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose)
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts C to F only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With Confirmed MCyR | 24.6 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With Confirmed MCyR | 38.9 percentage of participants |
| Cohort E: BP-CML/Ph+ ALL R-I | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With Confirmed MCyR | 20.8 percentage of participants |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With Confirmed MCyR | 15.2 percentage of participants |
Secondary
Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MCyR
MCyR is defined as percentage of participants with CCyR or PCyR. Cytogenetic response is the percentage of Ph+ metaphases in BM. Response is further defined as MCyR: CCyR or PCyR, where CCyR: no Ph+ cells; PCyR: 1 to 35% Ph+ cells.
Time frame: Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose)
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts C to F only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MCyR | 33.8 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MCyR | 55.6 percentage of participants |
| Cohort E: BP-CML/Ph+ ALL R-I | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MCyR | 27.1 percentage of participants |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MCyR | 34.8 percentage of participants |
Secondary
Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MMR
MMR is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript).
Time frame: Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose)
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts C to F only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MMR | 18.5 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MMR | 33.3 percentage of participants |
| Cohort E: BP-CML/Ph+ ALL R-I | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MMR | 18.8 percentage of participants |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MMR | 4.3 percentage of participants |
Secondary
Percentage of CP-CML Participants With CHR
Response criteria for CHR is reported as WBC≤institutional upper limit of normal, platelets\<450,000/mm\^3, no blasts or promyelocytes in peripheral blood, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, no extramedullary involvement (including no hepatomegaly or splenomegaly).
Time frame: Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose)
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts A and B only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of CP-CML Participants With CHR | 94.6 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of CP-CML Participants With CHR | 92.2 percentage of participants |
Secondary
Percentage of CP-CML Participants With Confirmed MCyR
Confirmed MCyR is defined as 2 assessments of CCyR or PCyR at least 28 days apart. For CP participants entering the trial in PCyR, confirmed MCyR is defined as 2 assessments of CCyR at least 28 days apart.
Time frame: Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose)
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts A and B only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of CP-CML Participants With Confirmed MCyR | 40.9 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of CP-CML Participants With Confirmed MCyR | 62.5 percentage of participants |
Secondary
Percentage of CP-CML Participants With Major Molecular Response (MMR)
MMR is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript).
Time frame: Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose)
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts A and B only.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: CP-CML R-I | Percentage of CP-CML Participants With Major Molecular Response (MMR) | 35.0 percentage of participants |
| Cohort B: CP-CML With T315I Mutation | Percentage of CP-CML Participants With Major Molecular Response (MMR) | 57.8 percentage of participants |
Secondary
Progression-free Survival (PFS)
PFS is defined as the interval from the first dose of study treatment until the criteria for progression or death are met, censored at the last response assessment. Progression from CP is reported as death, development of AP or BP, loss of CHR (in the absence of cytogenetic response), confirmed by development in complete blood counts (CBCs) at least 4 weeks apart, loss of MCyR, increasing WBC in participant without CHR defined by doubling of WBC to \>20K on 2 occasions at least 4 weeks apart; Progression from AP is reported as death, development of confirmed BP, loss of previous major or minor hematologic response over a 2-week period, no decrease from baseline levels in percentage blasts in peripheral blood or BM on all assessments over a 4-week period; Progression from BP or Ph+ ALL is reported as death, increasing blasts in peripheral blood or BM over a 4 week period.
Time frame: Every 12 weeks ± 2 weeks from last dose of study drug or the investigator/participant decision to discontinue treatment, whichever occurred later (Up to approximately 96 months after last dose)
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: CP-CML R-I | Progression-free Survival (PFS) | NA days |
| Cohort B: CP-CML With T315I Mutation | Progression-free Survival (PFS) | 1809.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Progression-free Survival (PFS) | 432.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Progression-free Survival (PFS) | 959.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Progression-free Survival (PFS) | 111.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Progression-free Survival (PFS) | 83.0 days |
Secondary
Time to Response
Time to response is defined as the interval from the first dose of study treatment until the criteria for response are first met, censored at the last assessment of response. Median time to response was estimated using the Kaplan-Meier method.
Time frame: Up to approximately 48 months after first dose
Population: Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. Median time to response was reported for responders only. Participants who did not achieve the specified response were censored at the last response assessment. Number analyzed: participants with data available at given time-point.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Cohort A: CP-CML R-I | Time to Response | Cytogenetic Response | 85.0 days |
| Cohort A: CP-CML R-I | Time to Response | Hematologic Response | 13.0 days |
| Cohort A: CP-CML R-I | Time to Response | Molecular Response | 173.0 days |
| Cohort B: CP-CML With T315I Mutation | Time to Response | Cytogenetic Response | 84.0 days |
| Cohort B: CP-CML With T315I Mutation | Time to Response | Hematologic Response | 10.0 days |
| Cohort B: CP-CML With T315I Mutation | Time to Response | Molecular Response | 167.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Time to Response | Cytogenetic Response | 113.5 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Time to Response | Hematologic Response | 21.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Time to Response | Molecular Response | 340.5 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Time to Response | Cytogenetic Response | 83.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Time to Response | Hematologic Response | 20.5 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Time to Response | Molecular Response | 335.5 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Time to Response | Cytogenetic Response | 28.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Time to Response | Hematologic Response | 28.0 days |
| Cohort E: BP-CML/Ph+ ALL R-I | Time to Response | Molecular Response | 56.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Time to Response | Hematologic Response | 24.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Time to Response | Molecular Response | 63.0 days |
| Cohort F: BP-CML or Ph+ ALL With T315I Mutation | Time to Response | Cytogenetic Response | 56.0 days |